논문검색
Author Young Joo Min, M.D.1, Cheol Won Suh, M.D.2, Keon Uk Park, M.D.2, Sung-Soo Yoon, M.D.3, Chan Hyung Park, M.D.4 and Hong Ghi Lee, M.D.4
Place of duty 1Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan; 2Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine; 3Department of Internal Medicine, Seoul National University College of Medicine; 4Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Title The Efficacy and Safety of DA-3030 (Recombinant Human Granulocyte Colony-Stimulating Factor) in Neutropenia after the Remission Induction Chemotherapy in Patients with Acute Myelogenous Leukemia
Publicationinfo Cancer Research and Treatment 2003 Feb; 035(01): 66-68.
Key_word Acute myelogenous leukemia, rhG-CSF, Neutropenia
Full-Text
Abstract Purpose: This study was conducted to determine the efficacy and safety of DA-3030 (a recombinant methionyl human granulocyte colony-stimulating factor, rhG-CSF), after remission induction chemotherapy, in patients with acute myelogenous leukemia (AML).

Materials and Methods: After the remission induction chemotherapy, with idarubicin (12 mg/m2/day for 3 days) and cytarabine (200 mg/m2/day for 7 days), 26 patients with newly diagnosed AML were assigned to receive DA-3030 (200μg/m2/day), starting 24 hours after the completion of the remission induction chemotherapy, until their neutrophil count recovered to greater than 1,000/μL for 3 consecutive days.

Results: The median time from the initiation of the chemotherapy to the neutrophil recovery of 1,000/μL was 21 days (range, 12∼41). Treatment with DA-3030 was not associated with significant adverse side effects. The most frequently reported side effects were musculo-skeletal pain (13%) and headache (13%).

Conclusion: The DA-3030 is a safe rhG-CSF for the treatment of neutropenia after remission induction chemotherapy in patients with AML. (Cancer Research and Treatment 2003;35:66⁣68)